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Continuous low pH viral inactivation has been considered by Boehringer Ingelheim, Pfizer, and other companies 
who are investing in integrated processing. In continuous viral inactivation, a critical parameter that poses a new 
challenge is the exact incubation time of the product stream. In a continuous space, the concept of time 
translates in the product flow rate, incubation volume, and dispersion effects. To address dispersion, we define 
the minimum residence time, tmin, as the time when the first product element exits the tubular chamber.  In this 
work, we characterize the tmin for a novel, scalable, and sturdy tubular reactor design that can serve as an 
incubation chamber for a process capable to produce >1kg of product. In addition, we provide robust data for a 
scale down model suitable for viral studies. We propose an innovative in-line spiking methodology to validate 
the minimum residence time using viruses. This methodology can be used as a viral clearance platform for 
continuous low pH virus inactivation.  Finally, we propose a trace response method to be used as a way to verify 
that the process was properly set up.  
 
 
  
 
